《大行報告》里昂升方達控股(01521.HK)目標價至5.7元 評級「買入」
里昂發表研究報告指出,醫藥研發合同研究機構(CRO)方達控股(01521.HK)於2021至2022年擴大其在內地服務覆蓋範圍,以迎合不斷增加的創新藥研發需求。雖然公司的產能擴張或對短期盈利造成壓力,但該行看好其一站式的CRO服務策略。
該行將方達控股的評級,由「買入」上調至「跑贏大市」,指其估值吸引,決定上調對其目標價由4.6元升至5.7元。
基於方達控股潛在新業務貢獻,里昂對方達控股2021至2022年收入預測上調各21至29%,但下調其盈利預測4至6%,以反映短期盈利壓力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.